- AtomVie Global Radiopharma collaborates with RLS & UPPI. This collaboration aims to strengthen AtomVie’s existing U.S. radiotherapeutic distribution network and is expected to enhance the supply chain of radiotherapeutics in the U.S.
AtomVie Global Radiopharma, a radiopharmaceutical contract development and manufacturing organisation (CDMO), has announced a strategic collaboration with RLS & UPPI. The partnership is aimed at strengthening AtomVie’s existing radiotherapeutic distribution network in the United States.
The collaboration comes at a time when the demand for radiotherapeutics is on the rise. By joining forces with RLS & UPPI, AtomVie aims to enhance its supply chain and ensure a steady supply of radiotherapeutics to healthcare providers across the country.
“Our commitment to transforming patients’ lives through high-quality radiopharmaceuticals is at the core of this partnership with RLS and UPPI,” said Bruno Paquin , CEO of AtomVie. He added: “These collaborations strengthen our ability to deliver critical radiopharmaceuticals to more locations, ensuring timely access for patients who depend on the products. These partnerships not only meet current demand but position us for future growth, as we expand significantly increased our manufacturing capacity and added commercial-scale capabilities.
Stephen Belcher , CEO of RLS, expressed confidence in the partnership’s impact on patient care, saying: “Radiopharmaceuticals begin to decay very quickly and it is essential that they reach patients in a safe and timely manner. That is why this partnership is so important. We are the experts in the last mile, and by adding our radiopharmacies to its network, AtomVie can ensure that its portfolio of life-enhancing therapeutic and diagnostic radiopharmaceuticals arrives at the right place at the right time, every time.”
John Witkowski, the President of UPPI, underscored the significance of the alliance, emphasising its role in enhancing access and improving the quality of life for individuals saying: “This partnership is an important step forward in improving access to radioisotope-based therapies and diagnostics that “They save lives. It reflects our joint commitment to providing precision medicine solutions for patients across the country.”
 Overview of outsourcing trends 
